Recruiting

Two new drugs combined to treat recurring ovarian cancer

Plain-English translation of NCT06660511 on ClinicalTrials.gov ↗ · Source last updated October 2024 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This early-stage trial is testing a combination of two medications: Disitamab Vedotin (an antibody-drug conjugate) and Anlotinib Hydrochloride (a targeted therapy). Together, they're designed to attack ovarian cancer cells that have returned after previous treatment and no longer respond to platinum-based chemotherapy. The study is looking at whether this combination is safe and effective for women whose tumors show a specific marker called HER2.

Women with recurring, platinum-resistant ovarian cancer have very few good treatment options right now. Current standard treatments have low success rates and cause significant side effects. This trial exists because researchers believe that targeting HER2-positive cancers with this new combination might offer better outcomes and a real hope for patients who have limited choices.

Do you qualify?

You likely qualify if…

you have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
your tumor shows HER2 expression based on a pathology test
your cancer has come back after initial treatment and is resistant to platinum-based chemotherapy
you are at least 18 years old and in generally good health with normal heart, liver, and kidney function
you have at least one measurable tumor that can be tracked on imaging
you are a woman of childbearing age willing to use reliable contraception throughout the study

You likely don't qualify if…

you have previously been treated with similar antibody-drug conjugate medicines or anti-angiogenic targeted therapies
you have untreated brain metastases (cancer that has spread to the brain)
you have had serious bleeding or blood clots in the past 4 weeks or 6 months respectively
you have severe heart disease, heart failure, or uncontrolled irregular heartbeats
you have active stomach ulcers, inflammatory bowel disease, or signs of bowel obstruction

What participation looks like

You would receive Disitamab Vedotin as an intravenous infusion every 2 weeks and take Anlotinib Hydrochloride capsules by mouth daily in a 2-weeks-on, 1-week-off pattern, with each treatment cycle lasting 21 days. The study will monitor you closely with blood tests and imaging scans to see how the cancer responds and watch for any side effects. Because this is an early-stage exploratory study, the trial is small (enrolling only 5 participants) and will help determine whether this combination is promising enough to study further.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(1 site)

China

Xiangya Second Hospital of Central South University, Changsha, Hunan

Key details

Phase

Safety & dosing

Sponsor

Second Xiangya Hospital of Central South University

Enrollment target

~5 participants

Started

October 2024

Primary completion

September 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Sex

Female only

Last updated on clinicaltrials.gov in October 2024.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

jingjing Wang

Second Xiangya Hospital of Central South University

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov